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FATAL PULMONARY HYPERTENSION AFTER HEART TRANSPLANTATION: SEQUELAE OF 
POSTACTINIC PULMONARY VASCULAR CHANGES 
Urs Niederhfiuser, MD, a Paul Vogt, MD, a Jakob Schneider, MD, b Edith R. Schmid, MD, ° Mico Tornic, MD, c 
Christian Gasser, MD, a Erwin Oechslin, MD, a and Marko I. Turina, MD, a Z~rich, Switzerland 
A 41-year-old woman was admitted for heart ransplan- 
tation because of doxorubicin-induced cardiomyopathy. 
In 1981, she had undergone combined treatment with 
chemotherapy and radiotherapy for Hodgkin's disease 
stage IIB and 9 years later for recurrent stage IIIB disease. 
The treatment included a total doxorubicin dose of 340 
mg and a total irradiation dose to the paraaortic space of 
3620 rads: She was in total remission for 4 years when her 
cardiomy0pathy was in an end stage and she showed 
catecholamine-dependent biventricular heart failure. Car- 
diac catheterization revealed a severe dilative cardiomy- 
opathy, probably caused by the toxic effects of doxorubi- 
cin. Pulmonary artery pressure was 55/32/38 mm Hg, and 
pulmonary vascular esistance was 331 dyn" sec. cm -5. 
Cardiac index was 1.73 L/m 2. 
In July 1994, orthotopic heart transplantation was per- 
formed. No residual tumor tissue was found. Before the 
aortic cr0ssclamp was opened, 1000 mg of methylpred- 
nisolone was administered asa standard immunosuppressive 
therapy. Total ischemic time was 77 minutes. A right-sided 
parietal p!eurectomy was performed to drain chronic benign 
effusion. Because of expected iffuse bleeding after pleurec- 
tomy, 2 million units of aprotinin were added to the extra- 
corporeal circulation (ECC). Weaning from cardiopulmo- 
nary bypass was accomplished without inotropic support. 
Seventeen minutes after decanulation and after initiation of 
heparin reversal with an infusion of protamine, a sudden rise 
of mean pulmonary artery pressure occurred, from 15 to 60 
mm Hg. Mean arterial pressure dropped from 68 to 20 mm 
Hg. Oxygenation remained adequate. The patient was im- 
mediately fully reheparinized, recannulated, and reperfused. 
All the following attempts to wean the patient from ECC 
failed because of a progressive rise of pulmonary artery 
pressure to suprasystemic levels, with maximal mean values 
of 90 mmHg and concomitant failure of the right side of the 
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heart. Inotropic substances (epinephrine, dopamine, and 
norepinephrine) were ineffective and nitroglycerin, prostag- 
landin El, and inhaled nitric oxide had no effect on pulmo- 
nary vascular esistance. Acute pulmonary artery emboliza- 
tion could be excluded. Even the implanted right ventricular 
assist device could not overcome the pulmonary vascular 
resistance. At a flow rate of 2 to 3 L/rain, pulmonary artery 
pressure was in excess of 90 mm Hg, with a systemic arterial 
pressure of 25 to 30 mm Hg. Inspiratory airway pressure rose 
to 40 cm H20, and the patient died of massive hemorrhagic 
pulmonary edema with failing oxygenation. At autopsy, the 
transplanted heart showed no relevant pathologic hanges. 
Significant alterations were found in the lungs, mostly in the 
venous and capillary circulation, with intravascular coagula- 
tion. The small pulmonary veins were narrowed by a loose, 
sparsely cellular intimal tissue suggestive of intimal swelling 
during operation (Fig. 1). The capillaries were filled with 
fibrin plugs, The lungs showed fibrosis in the pericardiac 
region, mostly as a result of former adiation, and a hemor- 
rhagic edema was present. Before operation, plasma protein 
levels were in the normal range and immunoelectrophoresis 
showed only a slight hypoimmunoglobulinemia, 
Adverse reaction to protamine. The patient had no 
predisposing factors toward adverse reactions to prota- 
mine (previous exposure to the drug, insulin dependence, 
fish allergy), 1 and the clinical picture of isolated and 
overwhelming pulmonary hypertension was not compati- 
ble with an immunoglobulin E-mediated anaphylaxis, 
which decreases systemic vascular resistance and increases 
capillary permeability and airway resistance. After admin- 
istration of 1 gm of methylprednisone, any anaphylactic 
reaction should also be diminished. The direct systemic 
vasodilatory effect of protamine was obviated by very slow 
rates of drug administration (5 mg/min). Protamine may 
also react with circulating immunoglobulin G or immuno- 
globulin M antibodies, which results in pulmonary vaso- 
constriction by elevation of anaphylatoxins and thrombox- 
ane A 2. Pulmonary hypertension was excessive, however, 
and could not be influenced by any vasodilatory drug as 
would be expected in thromboxane A2-related hyperten- 
sion. 2 Protamine-induced pulmonary hypertension in- 
volves the arterial vascular bed mainly by increasing the 
tone of arterioles, whereas in our patient he pathologic 
substrate was a predominant obstruction of the venous 
circulation, which best explains the impressive hereof- 
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Fig. 1. Small pulmonary venules are extremely narrowed 
by a sparsely cellular tissue. The loose appearance is 
suggestive of intimal swelling during the operation (van 
Gieson- elastin stain). 
rhagie pulmonary edema. However, overlapping symp- 
toms of venous and arterial pulmonary hypertension were 
not distinguishable during the operation. 
Adverse reaction to aprotinin. Aprotinin has character- 
istics similar to those of protamine. 3 The patient was not at 
risk for an anaphylactic reaction because she had never had 
contact with that drug before. Immunoglobulin G, immuno- 
globulin M, and immunoglobulin E antibodies could be 
ruled out. Moreover, the time course of the adverse reaction 
was not explained by complement activation, and the patient 
was not reactive to pulmonary vasodilators, which again 
would be expected in complement-dependent, thromboxane 
A2-induced pulmonary hypertension. Aprotinin is postu- 
lated to inhibit fibrinolysis and preserve platelet function, 
and it is used in cardiac operations to reduce blood loss and 
blood transfusion requirements. In our patient, aprotinin 
was indicated because of expected enhanced bleeding after 
additional parietal pleurectomy. Side effects have been re- 
ported with high-dose aprotinin therapy. 4 Especially in older 
patients, aprotinin may be responsible for disseminated 
intravascular coagulation if used in procedures with hypo- 
thermic irculatory arrest. Only low-dose aprotinin (2 million 
units) was used in our patient. Hypothermia was moderate 
(30 ° C core temperature), and circulatory arrest was never 
established. Low flow in the pulmonary circulation only 
occurred during ECC under full heparinization. The acti- 
vated clotting time was kept well above 400 seconds during 
the whole ECC to avoid inadequate anticoagulation. 
Postactinic pulmonary vascular changes. The most 
striking pathologic finding in our patient was an intimal 
thickening and consequent luminal narrowing of small pul- 
monary veins, as described by Wilkinson and Maclennan s in 
irradiated lungs. Radiation produces free radicals, mostly 
oxygen derived, and free radicals are predominantly found in 
the pulmonary veins, which have a higher oxygen saturation 
than the arteries. We believe that these postactinic and 
obstructing vascular changes were primarily responsible for 
the hypertension in the pulmonary circulation after the 
cessation of ECC. Reversal of heparinization by protamine 
and also aprotinin may have additionally contributed to 
hypercoagulability and to final intravascular coagulation in 
small pulmonary veins. Other than 2 units of fresh-frozen 
plasma, no other elevant coagulatory products were used. 
Pulmonary hypertension was fixed and did not respond to 
standard pulmonary vasodilators. The observed hemorrhagic 
pulmonary edema can be explained only b a venous form of 
pulmonary hypertension. The pulmonary side effects of 
doxorubicin and bleomycin are well known but are not 
explanatory in our case. The impressive swelling of the small 
pulmonary veins, with a luminal narrowing of up to 90%, 
must have occurred later during the operation, because if 
such changes had been present before operation, they would 
have resulted in much higher pulmonary artery pressure. We 
can only speculate about the cause of this swelling, and we 
assume a cofactorial pathogenesis of postacfinic vascular 
changes with Neomycin or doxorubicin toxic effects andECC. 
Conclusion. We suggest hat patients with postactinic 
changes of the pulmonary vascular system may be at 
increased risk for hypertension and intravascular coagu- 
lation in the pulmonary veins. We therefore recommend 
extensive valuation and careful perioperative monitoring 
of the coagulation state of these patients. Deep hypother- 
mia or circulatory arrest should be avoided, as should the 
administration of aprotinin or even protamine for reversal 
of heparin. Use of a heparin-coated ECC with low-dose 
heparinization might be advisable. The role of preopera- 
tive lung biopsy remains uncertain. 
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